Highest-ever Government Funding ($110M) from Congress and DOD Committed to Prostate Cancer Research

San Francisco, CA (UroToday.com) -- Bipartisan congressional support has increased funding for the Department of Defense’s Prostate Cancer Research Program (PCRP) to a historic level of $110M. This approved increase of $10M will begin in FY20, and will help seed more research projects to bring innovative breakthroughs from the science bench to the patients’ bedside. 

Prostate cancer — which kills a man every 17 minutes —  has only about a 30 percent survival rate once it reaches advanced stages, making new treatment options for those with advanced disease critical to survival.

“Patients with advanced prostate cancer, like Steve Bleser from North Carolina, have limited treatment options,” said ZERO CEO, Jamie Bearse.

“With this additional research funding from Congress, Steve and patients across the nation can now have hope that new breakthroughs will be in the pipeline. Amazing milestones like this only happen because of our dedicated and passionate champions from around the country who are tireless in advocating for our mission to end prostate cancer.”
Previous PCRP funding has led to the commercial development of four advanced prostate cancer treatments and one new diagnostic test. The four treatments are XGEVAⓇ, ZYTIGAⓇ, XTANDIⓇ, and ERLEADAⓇ. The advanced diagnostic test is the Oncotype DX AR-V7 Test.

Steve Bleser, an advanced prostate cancer patient in North Carolina, helped bring the increased funding by sharing his story with his elected officials in Congress. “I’ve done chemo, radiation, and many other treatments. My doctors say there are no more options for me,” said Bleser. “This is unacceptable. I won’t give up this fight — funding research is critical to help men like me live longer and have more tomorrows with our families."

Bleser is just one of the hundreds of fierce advocates and ZERO Champions from around the country who have attended the ZERO Prostate Cancer Summit, an annual advocacy event on Capitol Hill that brings awareness to the critical need for more prostate cancer research funding. 

This latest round of PCRP funding was championed by Congressional leaders with bipartisan support. Reps. Sanford Bishop (D-GA), Rep. Peter King (R-NY), and Sen. Mike Crapo (R-ID), and Sen. Robert Menendez (D-NJ) spearheaded the effort to secure PCRP funding, collecting signatures from more than 170 House and Senate members on letters to the appropriations committee. For more on this bill (HR 1158; DEPARTMENT OF DEFENSE APPROPRIATIONS ACT 2020), refer to page 323 of this PDF.

Source: "BREAKING: Congress Increases Prostate Cancer Research Funding To A Historic $110M Level | ZERO - The End Of Prostate Cancer". 2019. ZERO - The End Of Prostate Cancer